EP3530273C0 - A3 adenosin-rezeptorliganden zur verwendung in der behandlung sexueller funktionsstörungen - Google Patents

A3 adenosin-rezeptorliganden zur verwendung in der behandlung sexueller funktionsstörungen

Info

Publication number
EP3530273C0
EP3530273C0 EP19167869.7A EP19167869A EP3530273C0 EP 3530273 C0 EP3530273 C0 EP 3530273C0 EP 19167869 A EP19167869 A EP 19167869A EP 3530273 C0 EP3530273 C0 EP 3530273C0
Authority
EP
European Patent Office
Prior art keywords
treatment
sexual dysfunction
receptor ligands
adenosine receptor
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP19167869.7A
Other languages
English (en)
French (fr)
Other versions
EP3530273A2 (de
EP3530273A3 (de
EP3530273B1 (de
Inventor
Pnina Fishman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Can Fite Biopharma Ltd
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of EP3530273A2 publication Critical patent/EP3530273A2/de
Publication of EP3530273A3 publication Critical patent/EP3530273A3/de
Application granted granted Critical
Publication of EP3530273B1 publication Critical patent/EP3530273B1/de
Publication of EP3530273C0 publication Critical patent/EP3530273C0/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19167869.7A 2012-08-09 2013-08-08 A3 adenosin-rezeptorliganden zur verwendung in der behandlung sexueller funktionsstörungen Active EP3530273B1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL22138212 2012-08-09
IL22298812 2012-11-12
EP13750951.9A EP2892533A1 (de) 2012-08-09 2013-08-08 A3-adenosinrezeptorliganden zur verwendung bei der behandlung von sexueller dysfunktion
PCT/IL2013/050675 WO2014024195A1 (en) 2012-08-09 2013-08-08 A3 adenosine receptor ligands for use in treatment of a sexual dysfunction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP13750951.9A Division EP2892533A1 (de) 2012-08-09 2013-08-08 A3-adenosinrezeptorliganden zur verwendung bei der behandlung von sexueller dysfunktion

Publications (4)

Publication Number Publication Date
EP3530273A2 EP3530273A2 (de) 2019-08-28
EP3530273A3 EP3530273A3 (de) 2020-02-26
EP3530273B1 EP3530273B1 (de) 2024-08-14
EP3530273C0 true EP3530273C0 (de) 2024-08-14

Family

ID=49003954

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13750951.9A Withdrawn EP2892533A1 (de) 2012-08-09 2013-08-08 A3-adenosinrezeptorliganden zur verwendung bei der behandlung von sexueller dysfunktion
EP19167869.7A Active EP3530273B1 (de) 2012-08-09 2013-08-08 A3 adenosin-rezeptorliganden zur verwendung in der behandlung sexueller funktionsstörungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13750951.9A Withdrawn EP2892533A1 (de) 2012-08-09 2013-08-08 A3-adenosinrezeptorliganden zur verwendung bei der behandlung von sexueller dysfunktion

Country Status (11)

Country Link
US (1) US9549943B2 (de)
EP (2) EP2892533A1 (de)
JP (1) JP6140825B2 (de)
KR (1) KR101971762B1 (de)
CN (1) CN104619323B (de)
AU (1) AU2013301125B2 (de)
CA (1) CA2880753C (de)
IL (1) IL237107B (de)
MX (1) MX378538B (de)
RU (1) RU2015105407A (de)
WO (1) WO2014024195A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115779089A (zh) * 2022-11-28 2023-03-14 中国医学科学院肿瘤医院 用于治疗或改善雄性癌症及抑制其细胞系的药物的相关应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4788966A (en) 1987-05-14 1988-12-06 Inbae Yoon Plug for use in a reversible sterilization procedure
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
US5773423A (en) 1993-07-13 1998-06-30 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
AU1399297A (en) 1996-01-24 1997-08-20 Sumitomo Chemical Company, Limited Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production
WO1998039003A1 (en) * 1997-03-07 1998-09-11 Cerebrus Limited Use of (+)mefloquine for the treatment of malaria
CA2296485A1 (en) 1997-07-29 1999-02-11 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
US6048865A (en) 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
AU1363699A (en) 1997-10-23 1999-05-10 National Institute Of Health Methods for reducing ischemic injury of the heart via the sequential administ ration of monophosphoryl lipid a and adenosine receptor agents
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
CA2434906C (en) * 2001-01-16 2008-08-19 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
WO2002069906A2 (en) * 2001-03-06 2002-09-12 Cellegy Pharmaceuticals, Inc. Compounds and methods for the treatment of urogenital disorders
US20030143282A1 (en) * 2002-01-28 2003-07-31 Pnina Fishman Adenosine A3 receptor agonist
WO2004086034A2 (en) * 2003-03-28 2004-10-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3)
WO2007045989A1 (en) * 2005-10-20 2007-04-26 Pfizer Limited Pyridyl derivatives useful as h3 ligands
JP2009514846A (ja) * 2005-11-04 2009-04-09 ファイザー・リミテッド テトラヒドロナフチリジン誘導体
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
WO2008066627A2 (en) * 2006-10-24 2008-06-05 Board Of Regents, The University Of Texas System Adenosine signaling in diagnosis, treatment and prevention of priapism and erectile dysfunction
WO2009006089A2 (en) * 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A2 adenosine receptor agonists

Also Published As

Publication number Publication date
CA2880753C (en) 2019-09-10
HK1209342A1 (en) 2016-04-01
JP6140825B2 (ja) 2017-05-31
KR20150042232A (ko) 2015-04-20
RU2015105407A (ru) 2016-10-10
CA2880753A1 (en) 2014-02-13
US20150216889A1 (en) 2015-08-06
EP3530273A2 (de) 2019-08-28
CN104619323B (zh) 2018-03-09
US9549943B2 (en) 2017-01-24
CN104619323A (zh) 2015-05-13
IL237107A0 (en) 2015-03-31
MX378538B (es) 2025-03-10
EP3530273A3 (de) 2020-02-26
EP3530273B1 (de) 2024-08-14
AU2013301125A1 (en) 2015-02-12
KR101971762B1 (ko) 2019-08-13
BR112015002697A8 (pt) 2018-01-16
BR112015002697A2 (pt) 2017-10-31
EP2892533A1 (de) 2015-07-15
IL237107B (en) 2019-11-28
WO2014024195A1 (en) 2014-02-13
AU2013301125B2 (en) 2018-03-15
MX2015001644A (es) 2015-08-14
JP2015524465A (ja) 2015-08-24

Similar Documents

Publication Publication Date Title
SG11202012656WA (en) Heterocyclic compounds useful in the treatment of disease
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
HRP20180237T1 (hr) Metode za liječenje hcv-a
EP2726048A4 (de) Vorrichtung zur sexuellen stimulierung
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
LT2976074T (lt) Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis
EP2846784A4 (de) Verbindungen zur förderung des proteinabbaus und verfahren damit
EP2866826C0 (de) Kombination zur behandlung einer entzündlichen erkrankung
HRP20190600T1 (hr) Postupak za neinvazivnu procjenu genetičkih varijacija
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
SI2753334T1 (sl) Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjev
SG10201912275YA (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3kd related disorders
CO6870033A2 (es) Compuestos terapéuticos y métodos de uso relacionados
EP3251666C0 (de) Verfahren zur behandlung von neurotrauma
IL229582A0 (en) Antibodies against kir for the treatment of inflammatory disorders
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
SG11201509012QA (en) Sobetirome in the treatment of myelination diseases
PL2838539T3 (pl) Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych
HRP20170060T1 (hr) Derivati klor-pirazin karboksamida korisni za liječenje bolesti kojima pogoduje nedovoljna hidratacija sluznice
DK3040336T3 (da) Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
BR112013034055A2 (pt) alcaftadina para uso no tratamento de urticária
PL2768859T3 (pl) Antagoniści IL17C do leczenia zaburzeń zapalnych
DK2807170T3 (da) Phragmalin-limonoider til behandlingen af seksuel dysfunktion
HRP20181481T1 (hr) D-metadon za liječenje psihijatrijskih simptoma
ZA201308541B (en) Compounds for use in treatment of mucositis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2892533

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 15/10 20060101ALI20191004BHEP

Ipc: A61P 15/00 20060101ALI20191004BHEP

Ipc: A61K 31/4745 20060101AFI20191004BHEP

Ipc: A61K 31/7076 20060101ALI20191004BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 15/00 20060101ALI20200120BHEP

Ipc: A61K 31/4745 20060101AFI20200120BHEP

Ipc: A61P 15/10 20060101ALI20200120BHEP

Ipc: A61K 31/7076 20060101ALI20200120BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011453

Country of ref document: HK

17P Request for examination filed

Effective date: 20200626

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211129

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240311

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AC Divisional application: reference to earlier application

Ref document number: 2892533

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013086001

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20240910

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20240925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241115

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241114

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241114

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241114

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241214

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241115

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20250515

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 13

Effective date: 20250723

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250717

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20250901

Year of fee payment: 13

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40011453

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240814

U1N Appointed representative for the unitary patent procedure changed after the registration of the unitary effect

Representative=s name: MARKS & CLERK LLP; GB

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250808